Seeking Alpha

Seeking Alpha Portfolio App for iPad

2,042 people get PCYC articles and Market Currents by email alert.

Get email alerts on PCYC »

PCYC

Pharmacyclics, Inc.

5/23/2013, 3:59 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 1:39 PM Infinity Pharmaceuticals (INFI -20.5%) gets slammed by cautious comments out of JPMorgan today, saying that investors are "growing increasingly skittish" ahead of INFI's pending presentation at June's ASCO cancer conference. The company is expected to release Phase 1 clinical safety and tolerability data for IPI-145, its experimental leukemia drug, and while the investment bank predicts "a good showing," it may not be enough to outshine Gilead (GILD -2.3%), Pharmacyclics (PCYC -2.5%) or Roche (RHHBY.OB -0.6%). 3 Comments [Healthcare, On the Move]
Monday, May 13, 1:10 PM Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform and raises its price target to $100 from $70. The firm cites optimism over a number of upcoming catalysts for its leukemia drug Ibrutnib, which is being jointly developed by PCYC and JNJ's Janssen Pharmaceuticals. 1 Comment [Healthcare, On the Move]
Thursday, May 2, 6:24 AM Pharmacyclics (PCYC): Q1 EPS of -$0.40 misses by $0.23. Revenue of $2.85M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 1, 3:24 PM A number of biotechs are sharply lower amid rumors of a sizable Bio-fund going out of business and liquidating its positions. It's Ayer Capital Management according to sources, reports Adam Feuerstein. (PCYC -5.6%), (CLDX -4.9%), (NPSP -3.1%), (HALO -3.8%). 6 Comments [Healthcare, On the Move]
Thursday, April 11, 10:29 AM Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III clinical trial using Ibrutinib versus Chlorambucil to treat chronic lymphocytic leukemia and small lymphocyctic lymphoma has enrolled its fifth patient. The enrollment subsequently triggers a fourth $50M milestone payment obligation from JNJ's Janssen Biotech, who is collaborating with PCYC on Ibrutinib in oncology. On Monday, the drug was granted a 3rd "Breakthrough Therapy Designation" by the FDA. 1 Comment [Healthcare, On the Move]
Monday, April 8, 7:19 AM Pharmacyclics' (PCYC) ibrutinib is granted a 3rd "Breakthrough Therapy Designation" by the FDA for treatment of certain patients with leukemia and lymphoma. (PR) 2 Comments [Healthcare]
Monday, March 25, 2:23 PM Pharmacyclics (PCYC +2.3%) gains today on the back of positive comments out of Credit Suisse, saying they're excited about the multi-billion dollar potential of its lymphoma/leukemia drug ibrutinib, and see the recent weakness in the shares as a possible entry point. The firm has a target price of $90, which looks attainable with a number of positive catalysts on the horizon. Comment! [Healthcare, On the Move]
Friday, March 8, 9:09 AM Pharmacyclics (PCYC) prices a previously announced public offering of 2.2M common shares, representing ~3.1% of common shares currently outstanding, at $94.20/share. After soaring 63% YTD, it's a smart and opportunistic capital raise, Jon Ogg writes. Shares -0.2% premarket. Comment! [Healthcare]
Tuesday, February 19, 12:31 PM Pharmacyclics (PCYC -4.4%) slips after being downgraded to Market Perform at Leerink Swann on the back of its recent run. Leerink says that a number of key catalysts have already been realized, and further upside beyond its current valuation while possible, will require stronger sales numbers from ibrutinib than what's currently available. The firm raised its price target on the stock to $97 from $80. Comment! [Healthcare, On the Move]
Thursday, February 14, 4:51 PM More on Pharmacyclics (PCYC): FQ2 beats on both sales and EPS expectations. Revenue for the quarter consisted primarily of $50M in milestone revenue due to hitting a clinical milestone in connection with it's collaboration and license agreement with Janssen Biotech, plus $5M of license revenue related to its license agreement with Novo Nordisk under which Novo acquired exclusive worldwide rights to its small molecule Factor VIIa inhibitor, PCI-27483, for a restricted disease indication outside of oncology. Comment! [Earnings]
Thursday, February 14, 4:33 PM Pharmacyclics (PCYC): FQ2 EPS of $0.62 beats by $0.31. Revenue of $57.9M (-20% Y/Y) beats by $11M. (PR) Comment! [Healthcare, Earnings, Breaking News]
Thursday, February 14, 12:10 AM Notable earnings after Thursday’s close: A, ACTV, BGS, BRCD, CBS, CRAY, ELLI, GG, HMA, KEG, KYAK, MXWL, NR, PCYC, QLIK, VVC, WRI Comment! [Earnings]
Wednesday, February 13, 5:35 PM Notable earnings after Thursday’s close: A, ACTV, BGS, BRCD, CBS, CRAY, ELLI, GG, HMA, KEG, KYAK, MXWL, NR, PCYC, QLIK, VVC, WRI Comment! [Earnings]
Wednesday, February 13, 8:26 AM The FDA grants "breakthrough" status to blood-cancer treatment ibrutinib, which is being developed by Pharmacyclics (PCYC +3.7%) and J&J (JNJ), for two rare types of lymphoma. The designation was created last year and could enable drug approval after just an expanded early stage study. The companies now plan to file for authorization of Ibrutinib by the end of the year. (PR) Comment! [Healthcare]
Wednesday, January 30, 12:11 PM Pharmacyclics (PCYC +1%) moves higher in today's trading on an upgrade to Buy at TheStreet, citing the company's strong financials, "robust" revenue growth and a respectable return on equity. Comment! [Healthcare, On the Move]
Tuesday, December 11, 2012, 11:41 AM Pharmacyclics (PCYC +5.5%) says that follow-up findings from an ongoing Phase II study suggest that its investigational oral agent ibrutinib resulted in "high and durable responses" and was generally well toleratedin patients with relapsed or refractory mantle cell lymphoma. Comment! [Healthcare, On the Move]